Entrovas-49/51 Tablet

About Entrovas-49/51 Tablet

Entrovas-49/51 is a tablet combining sacubitril and valsartan, used in chronic heart failure with reduced ejection fraction. It helps lower the risk of cardiovascular death and hospital stay for heart failure, and is also used in children with symptomatic heart failure.

There are 25 brands of Sacubitril + Valsartan listed in Bangladesh. The lowest listed price is Arnis 24 mg+26 mg Tablet at ৳ 35.00 per unit.

What is Entrovas-49/51 Tablet?

Entrovas-49/51 is a tablet made by Renata PLC. It contains two active ingredients, sacubitril and valsartan, in a strength of 49 mg + 51 mg. Sacubitril belongs to a group called neprilysin inhibitors, and valsartan is an angiotensin receptor blocker. Together they work on the heart and blood vessels to support heart function in heart failure. It is used in adults with long-term heart failure and reduced ejection fraction, and in children aged one year and older with symptomatic heart failure. The exact dose and course are decided by the doctor.

Uses of Entrovas-49/51

Entrovas-49/51 is used to lower the risk of cardiovascular death and hospitalisation for heart failure in adults with chronic heart failure and reduced ejection fraction. It is also used to treat symptomatic heart failure with left ventricular systolic dysfunction in children aged one year and older. The doctor decides whether it is suitable, based on the patient's condition and other medicines being taken.

How to use Entrovas-49/51

Take Entrovas-49/51 as your doctor tells you. The doctor decides the dose and how long you take it. Swallow the tablet as directed; do not change the dose yourself. If you miss a dose, ask your doctor or pharmacist what to do. Do not stop taking it without medical advice, even if you feel better, because the doctor has planned the course for your heart condition.

Side effects of Entrovas-49/51

Like other medicines, Entrovas-49/51 can cause side effects. The most common ones include angioedema (swelling), low blood pressure, changes in kidney function, high potassium levels, cough and dizziness. Some side effects need medical attention. Tell your doctor or pharmacist if you notice any unusual symptoms, especially swelling of the face, lips or throat, or if you feel faint. The doctor will monitor you and decide if any change is needed.

Safety and precautions

Entrovas-49/51 must not be used if you have had angioedema related to an ACE inhibitor or ARB, or if you have hereditary angioedema. It should not be taken with ACE inhibitors or with aliskiren if you have diabetes. Tell your doctor about all medicines you take, including NSAIDs, potassium-sparing diuretics and lithium. Your doctor will check your kidney function and potassium. It is not recommended in severe liver impairment. Ask your doctor before use if you are pregnant, planning pregnancy or breastfeeding, or if you have kidney or liver problems.

Frequently asked questions

What kind of medicine is Entrovas-49/51 and what is it used for?

Entrovas-49/51 is a tablet containing sacubitril and valsartan. It is used in adults with chronic heart failure and reduced ejection fraction to lower the risk of cardiovascular death and hospital stay, and in children aged one year and older with symptomatic heart failure. The doctor decides if it is right for you.

What does the generic name sacubitril + valsartan mean?

The generic name shows the two active ingredients. Sacubitril is a neprilysin inhibitor, and valsartan is an angiotensin receptor blocker. Together they act on the heart and blood vessels. Entrovas-49/51 is one brand of this combination, made by Renata PLC.

Which medicines may interact with Entrovas-49/51?

It should not be taken with ACE inhibitors, or with aliskiren if you have diabetes. Use with another ARB should be avoided. Potassium-sparing diuretics may raise potassium levels, NSAIDs may increase the risk of kidney problems, and lithium may become more toxic. Always tell your doctor and pharmacist about every medicine you take.

Who should ask a doctor before taking Entrovas-49/51?

Ask your doctor first if you have had angioedema, kidney or liver problems, low blood pressure, or high potassium, or if you are pregnant, planning pregnancy or breastfeeding. Do not start or stop this medicine without medical advice. The doctor will check whether it is suitable for you.

Indications

This is indicated:
  • To reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class ll-IV) and reduced ejection fraction.
  • For the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older.
  • ... Read more
This is indicated:
  • To reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class ll-IV) and reduced ejection fraction.
  • For the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older.
  • This is usually administered in conjunction with other heart failure therapies, in place of an angiotensin-converting enzyme inhibitor (ACEi) or other ARB.

Pharmacology

This tablet contains a neprilysin inhibitor, sacubitril, and an angiotensin receptor blocker, valsartan. This tablet inhibits neprilysin (neutral endopeptidase; NEP) via LBQ657, the active metabolite of the prodrug sacubitril, and blocks the angiotensin II type-1 (AT1 ) receptor via valsartan. The cardiovascular and renal effects of this tablet in heart failure patients are attributed to the increased levels of peptides that are degraded by neprilysin, such as natriuretic peptides, by LBQ657, and the simultaneous inhibition of the effects of angiotensin II by valsartan. Valsartan inhibits the effects of angiotensin II by selectively blocking the AT1 receptor, and also inhibits angiotensin II-dependent aldosterone release.

Dosage & Administration

Adult Heart Failure: The recommended starting dose is 49/51 mg orally twice daily. Double the dose after 2 to 4 weeks to the target maintenance dose of 97/103 mg twice daily, as tolerated by the patient.

Reduce the starting dose to 24/26 mg twice daily for:
  • Patients not currently taking an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin II receptor blocker (ARB) or previously taking a low dose of these agents.
  • Patients with severe renal impairment.
  • Patients with moderate hepatic impairment.
Pediatric Heart Failure: Refer to Table 1 for the recommended dose for pediatric patients aged one year and older. Take the recommended dose orally twice daily. Adjust pediatric patient doses every 2 weeks, as tolerated by the patient.

Recommended Dose Titration-

Pediatric Patients Less than 40 kg:
  • Starting: 1.6 mg/kg
  • Second: 2.3 mg/kg
  • Final: 3.1 mg/kg
Pediatric Patients At least 40 kg, less than 50 kg:
  • Starting: 24/26 mg
  • Second: 49/51 mg
  • Final: 49/51 mg
Pediatric Patients At least 50 kg:
  • Starting: 49/51 mg
  • Second: 72/78 mg
  • Final: 97/103 mg

Interaction

Dual Blockade of the Renin-Angiotensin-Aldosterone System: Should not be used with an ACEi, aliskiren in patients with diabetes, and use with an ARB should be avoided.
Potassium-sparing Diuretics: Serum potassium level may be increased.
NSAIDs: Risk of renal impairment may be increased.
Lithium: Increased risk of lithium toxicity.

Contraindications

This combination is contraindicated:
  • In patients with hypersensitivity to any component
  • In patients with a history of angioedema related to previous ACE inhibitor or ARB therapy 
  • With concomitant use of ACE inhibitors. Do not administer within 36 hours of switching from or to an ACE inhibitor 
  • With concomitant use of aliskiren in patients with diabetes

Side Effects

The most common side effects are Angioedema, Hypotension, Impaired Renal Function, Hyperkalemia, Cough, Dizziness.

Pregnancy & Lactation

Pediatric Use: Safety and effectiveness have not been established in pediatric patients less than 1 year of age.

Geriatric Use: No relevant pharmacokinetic differences have been observed in elderly (>65 years) or very elderly (>75 years) patients compared to the overall population.
 
Hepatic Impairment: No dose adjustment is required when administering this tablet to patients with mild hepatic impairment (Child-Pugh A classification). This tablet is not recommended in patients with severe hepatic impairment, as no studies have been conducted in these patients.

Renal Impairment: No dose adjustment is required in patients with mild (eGFR 60 to 90 ml/min/1.73 m2) to moderate (eGFR 30 to 60 ml/min/1.73 m2) renal impairment. The recommended starting dose in patients with severe renal impairment (eGFR <30 ml/min/1.73 m2) is 24/26 mg twice daily.

Precautions & Warnings

This tablet may cause angioedema and must not be used in patients with a known history of angioedema related to previous ACEi or ARB therapy and in patients with hereditary angioedema.

This tablet lowers blood pressure and may cause symptomatic hypotension. Closely monitor serum creatinine, and down-titrate or interrupt this tablet in patients who develop a clinically significant decrease in renal function. In patients with renal artery stenosis, monitor renal function.

Monitor serum potassium periodically and treat appropriately, especially in patients with risk factors for hyperkalemia such as severe renal impairment, diabetes, hypoaldosteronism, or a high potassium diet. Dosage reduction or interruption of this tablet may be required.

Overdose Effects

Limited data are available with regard to overdosage in human subjects with this tablet. In healthy volunteers, a single dose of this tablet 583 mg sacubitril/617 mg valsartan, and multiple doses of 437 mg sacubitril/463 mg valsartan (14 days) have been studied and were well tolerated. Hypotension is the most likely result of overdosage due to the blood-pressure-lowering effects of this tablet. Symptomatic treatment should be provided. This tablet is unlikely to be removed by hemodialysis because of high protein binding.

Storage Conditions

Keep in a dry place and store below 30°C. Protect from moisture and keep out of the reach of children.

Alternative brands of Sacubitril + Valsartan

Other brands with the same generic name, cheapest first.

See all 25 brands

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.